DEALS: Abbott buys Kos in $3.7B deal


Abbott buys Kos in $3.7B deal


DEALS

WHO

WITH

WHAT

SCOOP

Abbott Laboratories

Kos Pharmaceuticals

$3.7B buyout

Kos makes Niaspan and Advicor, which boost "good" cholesterol, and is in late-stage development of Simcor.

Merck

Sirna Therapeutics

$1.1B buyout

Sirna's lead drug candidate, Sirna-027, is being developed as a treatment for wet, age-related macular degeneration.

Allergan

Groupe Corneal Laboratoires

$216M buyout

Allergan, which makes Botox, plans to separate the French companies' aesthetic and ophthalmic business with an eye to selling the ophthalmic division.

Wyeth

Ablynx

$212M licensing deals

Ablynx has agreed to license its Nanobodies technology to Wyeth.

Lonza

Genentech

$150M purchase

Switzerland's Lonza has struck a deal to buy a manufacturing plant in Spain from Genentech.

Inspire Pharmaceuticals

FAES Farma

$89M licensing deal

Inspire Pharmaceuticals gains U.S. and Canadian licensing rights to bilastine.

Wyeth

Inovio Biomedical

$64.5M deal

Wyeth will use Inovio Biomedical's DNA delivery technology for certain DNA vaccines in development.

Roche

InterMune

$60M deal

Roche has signed a deal to develop InterMune's experimental therapy for hepatitis C.

Biomira

ProlX Pharmaceuticals

$23.9 buyout

The acquisition will give Biomira control of Stimuvax, a synthetic MUC1 peptide vaccine now in Phase III, and PX-12, a thioredoxin inhibitor which is headed into Phase II.

Cephalon

Ambit

$18 deal

Cephalon is gaining access to Ambit's proprietary KinomeScan technology.

Merck

J. David Gladstone Institutes

$3.25M collaboration and licensing pact

The groups have signed a collaboration and licensing pact for the research and development of drugs to treat neurodegenerative diseases.

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.